Adrian W. Quartel net worth and biography

Adrian Quartel Biography and Net Worth

Insider of Zevra Therapeutics

Dr. Quartel was previously the Chief Medical Officer of Acer Therapeutics, where he played a key role in guiding clinical development, medical affairs and regulatory compliance. Zevra recently acquired Acer Therapeutics and his significant contributions there incorporating multiple rare disease assets into its portfolio gained prominence. Prior to that, he was the Chief Medical Officer at Adamas Pharmaceuticals, a company focused on drug development for neurological diseases. He previously served as the former Group Vice President of Global Medical Affairs at BioMarin Pharmaceuticals Inc., where he spearheaded the launch of six treatments for rare diseases or genetic disorders, including KUVAN®, VIMIZIM®, and Brineura®. Before his tenure at BioMarin, he oversaw clinical development and held senior medical leadership positions at Astellas, Chiltern, and ICON Clinical Research. Earlier in his career, Dr. Quartel worked as a clinical research fellow at UCLA Cedar Sinai and as a resident in cardio-thoracic surgery at Erasmus University Medical Center. He holds an M.D. from Erasmus University Medical School, Rotterdam, and has a postgraduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine in London. Dr. Quartel is board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom.

What is Adrian W. Quartel's net worth?: The estimated net worth of Adrian W. Quartel is at least $96.26 thousand as of January 30th, 2026. Quartel owns 9,723 shares of Zevra Therapeutics stock worth more than $96,258 as of March 17th. This net worth evaluation does not reflect any other assets that Quartel may own. Learn More about Adrian W. Quartel's net worth.
How do I contact Adrian W. Quartel?: The corporate mailing address for Quartel and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on Adrian W. Quartel's contact information.
Has Adrian W. Quartel been buying or selling shares of Zevra Therapeutics?: During the last quarter, Adrian W. Quartel has sold $40,026.39 of Zevra Therapeutics stock. Most recently, Adrian W. Quartel sold 4,533 shares of the business's stock in a transaction on Friday, January 30th. The shares were sold at an average price of $8.83, for a transaction totalling $40,026.39. Following the completion of the sale, the insider now directly owns 9,723 shares of the company's stock, valued at $85,854.09. Learn More on Adrian W. Quartel's trading history.
Who are Zevra Therapeutics' active insiders?: Zevra Therapeutics' insider roster includes Thomas Anderson (Director), John Bode (Director), R. Clifton (Chief Financial Officer & Treasurer), Tamara Favorito (Director), Neil McFarlane (President & Chief Executive Officer), Adrian Quartel (Insider), Timothy Sangiovanni (Senior Vice President, Corporate Controller), Joshua Schafer (Chief Commercial Officer), and Corey Watton (Director). Learn More on Zevra Therapeutics' active insiders.
Are insiders buying or selling shares of Zevra Therapeutics?: In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 7 times. They sold a total of 133,658 shares worth more than $1,273,867.64. The most recent insider tranaction occured on February, 3rd when SVP Timothy J Sangiovanni sold 3,000 shares worth more than $27,540.00. Insiders at Zevra Therapeutics own 2.4% of the company. Learn More about insider trades at Zevra Therapeutics.
Information on this page was last updated on 2/3/2026.

Adrian W. Quartel Insider Trading History at Zevra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/30/2026	Sell	4,533	$8.83	$40,026.39	9,723

Adrian W. Quartel Buying and Selling Activity at Zevra Therapeutics

Zevra Therapeutics Company Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Today's Range

Now: $9.90

$9.73

$10.11

50 Day Range

MA: $8.96

$8.31

$11.06

2 Week Range

Now: $9.90

$6.19

$13.16

Volume

1,320,158 shs

Average Volume

1,166,107 shs

Market Capitalization

$581.23 million

P/E Ratio

7.44

Dividend Yield

N/A

Beta

0.91